Evaluation of nuclear factor κb and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610

Meena Okera, Kyoungwha Bae, Eric Bernstein, Liang Cheng, Colleen Lawton, Harvey Wolkov, Alan Pollack, Adam Dicker, Howard Sandler, Christopher J. Sweeney

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

What's known on the subject? and What does the study add? Nuclear factor κB and CXCR4 are found in prostate cancer. The activation of NFκB may be able to be assessed for correlation of staining of NFκB subunits with staining of proteins products downstream of Nuclear Factor κB. Objective: To determine the frequency of nuclear factor κB (NFκB) and the chemokine receptor CXCR4 co-expression in prostate cancer specimens from men with locally advanced disease. Patients and methods: Paraffin-embedded samples from patients enrolled on the Radiation Therapy Oncology Group (RTOG) 8610 trial underwent immunohistochemical staining for NFκB and CXCR4. The amount of NFκB and CXCR4 was scored by a 'blinded' pathologist for the percentage of cells stained (0-100%) and staining intensity (0-3 +). Cox proportional hazard models were used for overall survival and disease-free survival to examine if NFκB and/or CXCR4 expression were associated with patient outcomes with and without adjustment for covariates. Results: Available material and successful staining allowed NFκB and CXCR4 status to be determined for 55 and 63 patients, respectively. Both NFκB and CXCR4 status were available for 51 patients. Of these, 53% were 2/3 + for cytoplasmic NFκB staining and 56% were 2/3 + for CXCR4. In all, 18 of the 51 patients were 2/3 + for both NFκB and CXCR4 (P= 0.129). Ten of 11 patients with 3 + NFκB had 2/3 + CXCR4 (P= 0.004). In this small study, neither NFκB nor CXCR4 were associated with prostate cancer outcomes. Conclusions: High NFκB expression is associated with CXCR4 expression and they are co-expressed in about one third of patients with clinically localized prostate cancer. Larger studies to accurately determine the frequency of co-expression and prognostic utility of NFκB and CXCR4 alone and in combination are warranted.

Original languageEnglish
JournalBJU International
Volume108
Issue number2 B
DOIs
StatePublished - Jul 2011

Fingerprint

Radiation Oncology
Chemokine Receptors
Prostatic Neoplasms
Radiotherapy
Staining and Labeling
Proportional Hazards Models
Paraffin
Disease-Free Survival
Survival

Keywords

  • CXCR4
  • NfκB
  • prostate cancer
  • radiation

ASJC Scopus subject areas

  • Urology

Cite this

Evaluation of nuclear factor κb and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. / Okera, Meena; Bae, Kyoungwha; Bernstein, Eric; Cheng, Liang; Lawton, Colleen; Wolkov, Harvey; Pollack, Alan; Dicker, Adam; Sandler, Howard; Sweeney, Christopher J.

In: BJU International, Vol. 108, No. 2 B, 07.2011.

Research output: Contribution to journalArticle

Okera, Meena ; Bae, Kyoungwha ; Bernstein, Eric ; Cheng, Liang ; Lawton, Colleen ; Wolkov, Harvey ; Pollack, Alan ; Dicker, Adam ; Sandler, Howard ; Sweeney, Christopher J. / Evaluation of nuclear factor κb and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. In: BJU International. 2011 ; Vol. 108, No. 2 B.
@article{adf858e917a34d63a35d623a83bad4a3,
title = "Evaluation of nuclear factor κb and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610",
abstract = "What's known on the subject? and What does the study add? Nuclear factor κB and CXCR4 are found in prostate cancer. The activation of NFκB may be able to be assessed for correlation of staining of NFκB subunits with staining of proteins products downstream of Nuclear Factor κB. Objective: To determine the frequency of nuclear factor κB (NFκB) and the chemokine receptor CXCR4 co-expression in prostate cancer specimens from men with locally advanced disease. Patients and methods: Paraffin-embedded samples from patients enrolled on the Radiation Therapy Oncology Group (RTOG) 8610 trial underwent immunohistochemical staining for NFκB and CXCR4. The amount of NFκB and CXCR4 was scored by a 'blinded' pathologist for the percentage of cells stained (0-100{\%}) and staining intensity (0-3 +). Cox proportional hazard models were used for overall survival and disease-free survival to examine if NFκB and/or CXCR4 expression were associated with patient outcomes with and without adjustment for covariates. Results: Available material and successful staining allowed NFκB and CXCR4 status to be determined for 55 and 63 patients, respectively. Both NFκB and CXCR4 status were available for 51 patients. Of these, 53{\%} were 2/3 + for cytoplasmic NFκB staining and 56{\%} were 2/3 + for CXCR4. In all, 18 of the 51 patients were 2/3 + for both NFκB and CXCR4 (P= 0.129). Ten of 11 patients with 3 + NFκB had 2/3 + CXCR4 (P= 0.004). In this small study, neither NFκB nor CXCR4 were associated with prostate cancer outcomes. Conclusions: High NFκB expression is associated with CXCR4 expression and they are co-expressed in about one third of patients with clinically localized prostate cancer. Larger studies to accurately determine the frequency of co-expression and prognostic utility of NFκB and CXCR4 alone and in combination are warranted.",
keywords = "CXCR4, NfκB, prostate cancer, radiation",
author = "Meena Okera and Kyoungwha Bae and Eric Bernstein and Liang Cheng and Colleen Lawton and Harvey Wolkov and Alan Pollack and Adam Dicker and Howard Sandler and Sweeney, {Christopher J.}",
year = "2011",
month = "7",
doi = "10.1111/j.1464-410X.2010.09884.x",
language = "English",
volume = "108",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2 B",

}

TY - JOUR

T1 - Evaluation of nuclear factor κb and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610

AU - Okera, Meena

AU - Bae, Kyoungwha

AU - Bernstein, Eric

AU - Cheng, Liang

AU - Lawton, Colleen

AU - Wolkov, Harvey

AU - Pollack, Alan

AU - Dicker, Adam

AU - Sandler, Howard

AU - Sweeney, Christopher J.

PY - 2011/7

Y1 - 2011/7

N2 - What's known on the subject? and What does the study add? Nuclear factor κB and CXCR4 are found in prostate cancer. The activation of NFκB may be able to be assessed for correlation of staining of NFκB subunits with staining of proteins products downstream of Nuclear Factor κB. Objective: To determine the frequency of nuclear factor κB (NFκB) and the chemokine receptor CXCR4 co-expression in prostate cancer specimens from men with locally advanced disease. Patients and methods: Paraffin-embedded samples from patients enrolled on the Radiation Therapy Oncology Group (RTOG) 8610 trial underwent immunohistochemical staining for NFκB and CXCR4. The amount of NFκB and CXCR4 was scored by a 'blinded' pathologist for the percentage of cells stained (0-100%) and staining intensity (0-3 +). Cox proportional hazard models were used for overall survival and disease-free survival to examine if NFκB and/or CXCR4 expression were associated with patient outcomes with and without adjustment for covariates. Results: Available material and successful staining allowed NFκB and CXCR4 status to be determined for 55 and 63 patients, respectively. Both NFκB and CXCR4 status were available for 51 patients. Of these, 53% were 2/3 + for cytoplasmic NFκB staining and 56% were 2/3 + for CXCR4. In all, 18 of the 51 patients were 2/3 + for both NFκB and CXCR4 (P= 0.129). Ten of 11 patients with 3 + NFκB had 2/3 + CXCR4 (P= 0.004). In this small study, neither NFκB nor CXCR4 were associated with prostate cancer outcomes. Conclusions: High NFκB expression is associated with CXCR4 expression and they are co-expressed in about one third of patients with clinically localized prostate cancer. Larger studies to accurately determine the frequency of co-expression and prognostic utility of NFκB and CXCR4 alone and in combination are warranted.

AB - What's known on the subject? and What does the study add? Nuclear factor κB and CXCR4 are found in prostate cancer. The activation of NFκB may be able to be assessed for correlation of staining of NFκB subunits with staining of proteins products downstream of Nuclear Factor κB. Objective: To determine the frequency of nuclear factor κB (NFκB) and the chemokine receptor CXCR4 co-expression in prostate cancer specimens from men with locally advanced disease. Patients and methods: Paraffin-embedded samples from patients enrolled on the Radiation Therapy Oncology Group (RTOG) 8610 trial underwent immunohistochemical staining for NFκB and CXCR4. The amount of NFκB and CXCR4 was scored by a 'blinded' pathologist for the percentage of cells stained (0-100%) and staining intensity (0-3 +). Cox proportional hazard models were used for overall survival and disease-free survival to examine if NFκB and/or CXCR4 expression were associated with patient outcomes with and without adjustment for covariates. Results: Available material and successful staining allowed NFκB and CXCR4 status to be determined for 55 and 63 patients, respectively. Both NFκB and CXCR4 status were available for 51 patients. Of these, 53% were 2/3 + for cytoplasmic NFκB staining and 56% were 2/3 + for CXCR4. In all, 18 of the 51 patients were 2/3 + for both NFκB and CXCR4 (P= 0.129). Ten of 11 patients with 3 + NFκB had 2/3 + CXCR4 (P= 0.004). In this small study, neither NFκB nor CXCR4 were associated with prostate cancer outcomes. Conclusions: High NFκB expression is associated with CXCR4 expression and they are co-expressed in about one third of patients with clinically localized prostate cancer. Larger studies to accurately determine the frequency of co-expression and prognostic utility of NFκB and CXCR4 alone and in combination are warranted.

KW - CXCR4

KW - NfκB

KW - prostate cancer

KW - radiation

UR - http://www.scopus.com/inward/record.url?scp=79960107662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960107662&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2010.09884.x

DO - 10.1111/j.1464-410X.2010.09884.x

M3 - Article

VL - 108

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2 B

ER -